MENU
NTRA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

NTRA stock forecast, quote, news & analysis

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology... Show more

Industry: #Biotechnology
NTRA
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for NTRA with price predictions
Sep 22, 2026

NTRA's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for NTRA turned positive on September 17, 2026. Looking at past instances where NTRA's MACD turned positive, the stock continued to rise in 46 of 51 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on NTRA as a result. In 79 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

Following a +5.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 241 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 237 of 281 cases where NTRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

NTRA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (30.960) is normal, around the industry mean (60.700). P/E Ratio (0.000) is within average values for comparable stocks, (144.546). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.432). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 19.68B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 4%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 55%. GRAL experienced the highest price growth at 43%, while ADVB experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 7%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was 25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 61
Price Growth Rating: 41
SMR Rating: 78
Profit Risk Rating: 90
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
NTRA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a genetic testing company which develops proprietary bioinformatics-based technology

Industry MedicalSpecialties

Industry
Biotechnology
Address
13011 McCallen Pass
Phone
+1 650 980-9190
Employees
6140
Web
https://www.natera.com
NTRA's MACD Histogram just turned positive